The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Real-world clinical and molecular NSCLC data in Biomarkers ATLAS
Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, comments on the role of Biomarkers ATLAS, an integrated knowledge-based database, in optimizing personalized treatment for patients with non-small cell lung cancer (NSCLC). It collects data from patients across multiple Italian institutions, focusing on the harmonization of molecular and clinical data such as mutations in EGFR, KRAS, BRAF, and ALK. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
